---
title: "Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281907259.md"
description: "Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial"
datetime: "2026-04-07T15:52:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281907259.md)
  - [en](https://longbridge.com/en/news/281907259.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281907259.md)
---

# Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial

Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LEXX.US](https://longbridge.com/en/quote/LEXX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)](https://longbridge.com/en/news/286648301.md)
- [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md)
- [BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO](https://longbridge.com/en/news/287276384.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)
- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)